caa a22 4500 469116587 CHVBK 20180323133126.0 cr unu---uuuuu 170328e19920501xx s 000 0 eng 10.1007/BF00172941 doi (NATIONALLICENCE)springer-10.1007/BF00172941 The MTT assay for chemosensitivity testing of human tumors of the central nervous system [Elektronische Daten] Part I.: Evaluation of test-specific variables [G. Nikkhah, J. Tonn, O. Hoffmann, H. Kraemer, J. Darling, R. Schönmayr, W. Schachenmayr] Summary: The aim of this study was to optimize the experimental conditions of the MTT assay for primary cultures of human brain tumors. This assay is based on the mitochondrial reduction of MTT-(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) salt to formazan crystals by living cells. Formazan can be quantified spectrophotometrically. This assay measures the antimetabolic and, by using an adequate recovery period for the cells, also the antiproliferative effects of cytotoxic drugs. Our results suggest the following experimental design for its application as an chemosensitivity assay for human brain tumors: 1-h drug exposure followed by a seven days recovery period without drugs. Then tumor cells are incubated 4 hours with 1 mg MTT/ml and final absorbance readings are performed at 550 nm and 630 nm as test and reference wavelengths respectively. In this way, the assay seems to be a reliable and simple method for rapid chemosensitivity testing in human brain tumors. Kluwer Academic Publishers, 1992 MTT assay nationallicence test variables nationallicence brain tumors nationallicence chemosensitivity test nationallicence cell culture nationallicence Nikkhah G. Institute of Neuropathology, Giessen, Germany aut Tonn J. Departments of Neurosurgery, Giessen, Germany aut Hoffmann O. Departments of Neurosurgery, Giessen, Germany aut Kraemer H. Behring-Werke A G, Marburg, Germany aut Darling J. Institute of Neurology, London, UK aut Schönmayr R. Nordstadt Hospital, Hannover, Germany aut Schachenmayr W. Institute of Neuropathology, Giessen, Germany aut Journal of Neuro-Oncology Kluwer Academic Publishers 13/1(1992-05-01), 1-11 0167-594X 13:1<1 1992 13 11060 https://doi.org/10.1007/BF00172941 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00172941 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Nikkhah G. Institute of Neuropathology, Giessen, Germany aut NATIONALLICENCE 700 1- Tonn J. Departments of Neurosurgery, Giessen, Germany aut NATIONALLICENCE 700 1- Hoffmann O. Departments of Neurosurgery, Giessen, Germany aut NATIONALLICENCE 700 1- Kraemer H. Behring-Werke A G, Marburg, Germany aut NATIONALLICENCE 700 1- Darling J. Institute of Neurology, London, UK aut NATIONALLICENCE 700 1- Schönmayr R. Nordstadt Hospital, Hannover, Germany aut NATIONALLICENCE 700 1- Schachenmayr W. Institute of Neuropathology, Giessen, Germany aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 13/1(1992-05-01), 1-11 0167-594X 13:1<1 1992 13 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence SWISSBIB 469116560 BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer